Kopran Limited Stock Price Today (NSE: KOPRAN)
Fundamental Score
Kopran Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kopran Limited share price today is ₹260.86, up +4.39% on NSE/BSE as of 16 September 2026. Kopran Limited (KOPRAN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.26K (Cr). The 52-week high for KOPRAN share price is ₹274.78 and the 52-week low is ₹107.00. At a P/E ratio of 50.46x, KOPRAN is currently trading above its industry average P/E of 34.89x. 0
Kopran Limited Share Price Chart — NSE/BSE Historical Performance
Kopran Limited share price chart: 32.70% return over the past month. 52-week high ₹274.78, 52-week low ₹107.00.
Kopran Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹251.50 | ₹274.78 | ₹237.78 | ₹260.86 | 142.27L (Cr) | |
| ₹235.26 | ₹267.00 | ₹233.15 | ₹249.90 | 158.58L (Cr) | |
| ₹235.75 | ₹237.60 | ₹226.20 | ₹235.26 | 4.00L (Cr) | |
| ₹235.50 | ₹242.90 | ₹234.30 | ₹235.82 | 2.82L (Cr) | |
| ₹237.41 | ₹238.90 | ₹231.39 | ₹234.37 | 3.64L (Cr) | |
| ₹245.87 | ₹249.99 | ₹235.00 | ₹239.51 | 8.09L (Cr) | |
| ₹234.20 | ₹253.71 | ₹230.50 | ₹245.87 | 20.37L (Cr) | |
| ₹232.40 | ₹242.80 | ₹229.29 | ₹232.54 | 6.61L (Cr) | |
| ₹220.89 | ₹239.60 | ₹218.84 | ₹232.24 | 14.56L (Cr) | |
| ₹215.25 | ₹220.40 | ₹214.04 | ₹218.81 | 2.13L (Cr) |
Kopran Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹217.83 | ₹274.78 | ₹214.00 | ₹260.86 | +19.75% | |
| ₹188.22 | ₹235.07 | ₹166.00 | ₹217.83 | +15.73% | |
| ₹190.00 | ₹216.00 | ₹179.93 | ₹191.03 | +0.54% | |
| ₹197.40 | ₹213.50 | ₹175.00 | ₹189.31 | -4.10% | |
| ₹164.63 | ₹219.00 | ₹147.65 | ₹206.27 | +25.29% | |
| ₹111.50 | ₹166.60 | ₹110.24 | ₹164.63 | +47.65% | |
| ₹128.00 | ₹130.58 | ₹107.00 | ₹108.04 | -15.59% | |
| ₹125.00 | ₹146.83 | ₹119.81 | ₹131.83 | +5.46% | |
| ₹151.40 | ₹157.85 | ₹125.27 | ₹128.05 | -15.42% | |
| ₹133.50 | ₹159.89 | ₹127.52 | ₹150.43 | +12.68% | |
| ₹163.60 | ₹167.95 | ₹123.11 | ₹134.49 | -17.79% | |
| ₹174.36 | ₹184.00 | ₹164.61 | ₹165.37 | -5.16% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kopran Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kopran Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KOPRAN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 1.76)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.77%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 50.46x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-10.05%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-17.84% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-16.05% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-124.83 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.51%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Kopran Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kopran Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kopran LimitedKopran Limited...Selected✓ KOPRAN • 524280 | 41.3/100 | ₹260.86₹261 | ₹1259.58₹1259.58 | 50.46Average 50.5 Average | 0.00%Poor 0.00% Poor | 7.77%Poor 7.77% Poor | 0.29Excellent 0.3 Excellent | -16.05%Poor -16.05% Poor | 6.74%Good 6.74% Good | 1.47% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Kopran Limited PE Ratio History
Historical price-to-earnings ratio for KOPRAN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹7.99 | ₹150.43 | 18.8x |
| FY 2024 | ₹10.55 | ₹211.78 | 20.1x |
| FY 2023 | ₹5.65 | ₹241.25 | 42.7x |
| FY 2022 | ₹13.77 | ₹150.85 | 11x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Kopran Limited Dividend History
Annual cash dividends paid by KOPRAN — dividend yield 1.47%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.46 Cr |
| FY 2024 | ₹14.46 Cr |
| FY 2023 | ₹14.46 Cr |
| FY 2022 | ₹6.49 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Kopran Limited Quarterly Performance
Latest quarterly metrics for KOPRAN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-10.05%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-16.05%
Compounded annual net profit growth over 5 years
Kopran Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KOPRAN — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Kopran Limited Financial Statements
Annual income statement, balance sheet and cash flow for Kopran Limited (KOPRAN) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Kopran Limited
About KOPRAN (Kopran Limited)
Kopran Ltd is a pharmaceutical entity forging a path in the global landscape, distinguished by its comprehensive approach to healthcare solutions. The company deftly navigates the ...spectrum from foundational active pharmaceutical ingredients (APIs) to the creation of diverse finished dosage forms. With a commitment to accessibility, Kopran addresses a wide range of medical needs, crafting formulations that include both branded innovations and widely accessible generic alternatives. This dedication to providing diverse options allows them to cater to varied patient populations across both India and the global stage, reinforcing their commitment to widespread health accessibility. The company's manufacturing prowess is evident in its extensive product portfolio, encompassing an array of dosage forms designed to meet diverse patient requirements. From easily administered tablets and capsules to convenient syrups and suspensions, and even advanced injectables and specialized dry powder formulations, Kopran demonstrates a versatility that sets it apart. This breadth of capabilities allows them to deliver therapeutic solutions that are tailored to specific conditions and patient preferences, ensuring optimal treatment outcomes. The meticulous attention to detail in each stage of production underscores their commitment to quality and patient well-being. Kopran's therapeutic focus encompasses a broad spectrum of prevalent health challenges. Their product offerings include critical medications across several important categories, such as macrolides for managing infections, potent antibacterials to combat resistant strains, and anticonvulsants for neurological care. Additionally, they provide essential anti-hypertensive drugs for cardiovascular health, and effective anti-helminth medications for parasite control. This strategic targeting of key therapeutic areas demonstrates Kopran's dedication to addressing pressing global health needs, contributing to the overall improvement of patient care and well-being across diverse communities.
Company Details
Key Leadership
KOPRAN Share Price: Frequently Asked Questions
What is the current share price of Kopran Limited?
Kopran Limited (KOPRAN) trades at ₹260.86 on NSE and BSE. Market cap ₹1.26K (Cr). Educational data only.
What is the P/E ratio of Kopran Limited?
Kopran Limited has a P/E of 50.46x vs industry average 34.89x.
What is the Bull Run score for Kopran Limited?
Kopran Limited has a Bull Run score of 41.3/100 based on 25+ financial parameters.
Does Kopran Limited pay dividends?
Kopran Limited has a dividend yield of 1.47%. Past dividends don't guarantee future payments.
What is the ROE of Kopran Limited?
Kopran Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kopran Limited?
Kopran Limited has debt-to-equity of 0.29.
Is Kopran Limited a good investment?
Bull Run gives Kopran Limited a score of 41.3/100. This is not investment advice — consult a SEBI-registered advisor.